1) Clinical, biochemical and genetic aspects of patients suffering from a pyrimidine degradation defect.
2) Pharmacogenetic aspects associated with inborn errors of purine and pyrimidine metabolism
3) Pre-clinical screening of drug combinations for neuroblastoma. Optimising current treatment modalities through targeting the PI3K/Akt pathway.
4) Catecholamine excretion in neuroblastoma: identification of catecholamine metabolites profiles associated with clinical and genetic characteristics of neuroblastoma
Theme: Metabolic Disorders and Oncology
This research group participates in the Amsterdam Center for Metabolism